New hope for tough lung cancers: triple therapy trial targets progression
NCT ID NCT05781308
First seen Nov 18, 2025 · Last updated Jun 16, 2026 · Updated 21 times
Summary
This study tests whether adding an immunotherapy drug (atezolizumab) to a standard two-drug chemotherapy (paclitaxel and bevacizumab) can help people with advanced non-squamous lung cancer whose disease has worsened after prior immunotherapy and chemotherapy. About 156 participants will be randomly assigned to receive either the two-drug or three-drug combination. The main goal is to see if the three-drug combo can keep the cancer from growing for at least 6 months in more patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHM Hôpital Nord
Marseille, France
-
CH Annecy Genevois
Pringy, France
-
CH Avignon
Avignon, France
-
CH Cholet
Cholet, France
-
CH Côte Basque
Bayonne, France
-
CH Le Mans
Le Mans, France
-
CH Pasteur
Colmar, France
-
CH Pau
Pau, France
-
CH Versailles
Le Chesnay, France
-
CH Villefranche Nord Ouest
Villefranche-sur-Saône, 69655, France
-
CHD Vendée
La Roche-sur-Yon, France
-
CHR Orléans
Orléans, France
-
CHU Amiens
Amiens, France
-
CHU Besançon - Hôpital J. MINJOZ
Besançon, 25030, France
-
CHU Bordeaux Haut-Lévèque
Pessac, France
-
CHU Côte de Nacre
Caen, 14000, France
-
CHU Dijon
Dijon, France
-
CHU Gabriel Montpied
Clermont-Ferrand, France
-
CHU Lille
Lille, France
-
CHU Limoges
Limoges, 87042, France
-
CHU Poitiers
Poitiers, France
-
CHU Rouen
Rouen, 76031, France
-
CHU Saint Etienne
Saint-Etienne, France
-
CHU Toulouse
Toulouse, 31059, France
-
CHU Tours
Tours, France
-
CHU d'Angers
Angers, 49033, France
-
Centre Georges-François Leclerc
Dijon, 21079, France
-
Centre Hospitalier Intercommunal Créteil CHIC
Créteil, France
-
Centre Léon Bérard
Lyon, 69373, France
-
Chu Grenoble
Grenoble, 38043, France
-
Clinique Teissier
Valenciennes, France
-
GHR Mulhouse et Sud Alsace GHRMSA
Mulhouse, 68070, France
-
Groupe Hospitalier Paris Saint Joseph GHPSJ
Paris, France
-
HIA Sainte-Anne
Toulon, 83800, France
-
Hospices Civils de Lyon - URCOT
Pierre-Bénite, France
-
Hôpital APHP Ambroise Paré
Boulogne, 92104, France
-
Hôpital BICHAT
Paris, 75877, France
-
Hôpital Européen
Marseille, France
-
Hôpital TENON
Paris, 75970, France
-
Hôpitaux Privés de Metz Robert Schuman
Metz, France
-
Institut Paoli Calmettes
Marseille, 13273, France
-
Institut de Cancerologie de l'Ouest ICO
Saint-Herblain, France
-
Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091, France
-
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, France
Conditions
Explore the condition pages connected to this study.